Male OAB

Overactive bladder is a treatable medical condition that is estimated to affect more than 33 million people in the United States.

Welcome

Rethinking Treatment of Men With Lower Urinary Tract Symptoms

Overactive bladder (OAB) is defined as urgency, with or without urgency incontinence, usually with frequency and nocturia. Although OAB occurs with similar frequency in men and women, it is diagnosed and treated much more often in women. This discrepancy may be explained by the fact that women with OAB are more likely to present with urgency incontinence as a symptom, whereas male OAB patients are usually continent.

OAB symptoms in men generally occur as part of a broader symptom complex known as lower urinary tract symptoms (LUTS), which includes voiding and storage symptoms.

OAB symptoms commonly occur in conjunction with prostate disorders (often described as benign prostate hypertrophy, benign prostate enlargement, and benign prostatic obstruction, bladder outlet obstruction). Treatment of these prostatic disorders may not always resolve OAB symptoms.

This presentation discusses the symptomatology and diagnosis of OAB in men and reviews the available clinical trial data on the use of tolterodine alone and in combination with alpha-blockers in male patients with LUTS.

At the end of the presentation, participants should be able to:

List the symptoms of OAB in men
List some conditions that may be associated with OAB symptoms in men
Discuss the role of tolterodine in the treatment of men with LUTS

Regional Teleconferences

Each regional teleconference will be approximately 40 minutes in duration as follows:

5 minute welcome/introduction
25 minute presentation
10 minute Q&A session

To register for this teleconference enter you email address below and click the "Register" button.

This website is intended for healthcare professionals only.

To register for this teleconference enter your email address here.

If you are already registered you may log in below to manage your profile.

Looking to join a meeting?

Enter Meeting ID:

Indications And Usage

DETROL LA Capsules are once daily extended release capsules indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Important Considerations

Detrol LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients.

Patients with the following conditions should be treated with caution: renal impairment, bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduce hepatic function.

Dry mouth was the most frequently reported adverse event (DETROL LA 23% vs placebo 8%); others (≥4%) included headache (DETROL LA 6% vs placebo 4%), constipation (DETROL LA 6% vs placebo 4%), and abdominal pain (DETROL LA 4% vs placebo 2%).

Please see full Prescribing Information

Source IMS

*Source: IMS Midas Global Sales Audit, Verispan Longitudinal Data, based on total prescriptions of DETROL and DETROL LA for OAB from April 1998-June 2005.